Advanced in Mitochondrial Complex 2 Deficiency

Peter Kannu

Alberta Health Services
Edmonton, AB, CA 
Advanced in Mitochondrial Complex 2 Deficiency
Alberta Health Services
Edmonton, AB, CA 
OverviewLocationsClinical Research

Overview

Peter Kannu practices in Edmonton, Canada. Mr. Kannu is rated as an Advanced expert by MediFind in the treatment of Mitochondrial Complex 2 Deficiency. His top areas of expertise are Fibrodysplasia Ossificans Progressiva, Achondroplasia, Neurofibromatosis, and Neurofibromatosis Type 1 (NF1).

His clinical research consists of co-authoring 79 peer reviewed articles and participating in 4 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 1 article in the study of Mitochondrial Complex 2 Deficiency.

Gender
Male

Locations

Alberta Health Services
Edmonton, AB, Canada

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

4 Clinical Trials

Prospective Clinical Assessment Study in Children With Achondroplasia: The PROPEL Trial
Prospective Clinical Assessment Study in Children With Achondroplasia: The PROPEL Trial
Enrollment Status: Active_not_recruiting
Publish Date: April 11, 2025
Phase 2, Open-Label, Dose-Escalation and Dose-Expansion Study of Infigratinib, an FGFR 1-3-Selective Tyrosine Kinase Inhibitor, in Children With Achondroplasia: PROPEL 2
Phase 2, Open-Label, Dose-Escalation and Dose-Expansion Study of Infigratinib, an FGFR 1-3-Selective Tyrosine Kinase Inhibitor, in Children With Achondroplasia: PROPEL 2
Enrollment Status: Completed
Publish Date: March 26, 2025
Intervention Type: Drug
Study Drug: Infigratinib
Study Phase: Phase 2
A Phase 3, Efficacy and Safety Study of Oral Palovarotene for the Treatment of Fibrodysplasia Ossificans Progressiva (FOP)
A Phase 3, Efficacy and Safety Study of Oral Palovarotene for the Treatment of Fibrodysplasia Ossificans Progressiva (FOP)
Enrollment Status: Completed
Publish Date: November 29, 2023
Intervention Type: Drug
Study Drug: Palovarotene
Study Phase: Phase 3
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Efficacy and Safety Study of Palovarotene in Subjects With Multiple Osteochondromas
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Efficacy and Safety Study of Palovarotene in Subjects With Multiple Osteochondromas
Enrollment Status: Terminated
Publish Date: August 01, 2022
Intervention Type: Other, Drug
Study Phase: Phase 2
View 3 Less Clinical Trials

79 Total Publications

Corrigendum to "Multigenerational genetic inheritance and clinical characteristics of the rare disease hypophosphatasia in 6 families: A case series" [Bone Rep. 26 (2025) 1-6 (101857)].
Corrigendum to "Multigenerational genetic inheritance and clinical characteristics of the rare disease hypophosphatasia in 6 families: A case series" [Bone Rep. 26 (2025) 1-6 (101857)].
Journal: Bone reports
Published: September 22, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Kannu's expertise for a condition
ConditionClose
    View All 21 Advanced Conditions
    View All 50 Experienced Conditions
    Want to save this expert for later?
    Sign Up
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile